MCC22 / University of Minnesota - LARVOL DELTA

Fabrication of metal incorporated polymer composite: An excellent antibacterial agent. (PubMed, J Mol Struct) - "Further, the in vitro antibacterial activities of the metal incorporated-COL has been performed by standard methods against B. cereus (MCC2243) (gram-positive) and E. coli (MCC2412) (gram-negative) bacteria...These results suggest that the synthesized material may act a potential candidate for low cost, environment friendly antibacterial agents and may find their application in clinical fields. Herein we are also proposing mechanism of antibacterial activity."

Journal

The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward. (PubMed, Neuropharmacology) - "Furthermore, MCC22 did not alter motor function and did not exhibit rewarding properties. Given the exceptional potency of MCC22 without tolerance or reward, MCC22 has the potential to vastly improve management of chronic pain due to CIPN."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Gene Therapies • Neuralgia • Oncology • Pain

Combined glia inhibition and opioid receptor agonism afford highly potent analgesics without tolerance. (PubMed, ACS Chem Neurosci) - "MK-801 and Ro25-6981 antagonism of MMG22 antinociception, but not MCC22, is consistent with selective inhibition of activated NMDAR in astrocytes. It is concluded that i.t. MMG22 and MCC22 produce exceptional antinociception via potent inhibition of activated spinal glia, thereby leading to desensitization of spinal neurons and enhanced activation of neuronal MOR. Thus, the present study suggests a new approach to treatment of chronic inflammatory pain without tolerance through a single molecular entity that simultaneously inhibits activated glia and stimulates MOR in spinal neurons."

Journal

Production, characterization and bioinformatics analysis of L-asparaginase from a new Stenotrophomonas maltophilia EMCC2297 soil isolate. (PubMed, AMB Express) - "Maximum production of about 8 IU/ml/h was obtained with 0.4% dextrose, 0.1% yeast extract and 10 mM magnesium sulphate. In conclusion L-asparaginase of the recovered Stenotrophomonas maltophilia EMCC2297 isolate has characters enabling it to be used for medical therapeutic application."

Journal

Reduction of chromium-VI by chromium-resistant Escherichia coli FACU: a prospective bacterium for bioremediation. (PubMed, Folia Microbiol (Praha)) - "The FACU (EMCC 2289) 16S rRNA sequence and the ChrR-partially isolated gene were submitted to the DDBJ under acc. # numbers LC177419 and LC179020, respectively. The results support that FACU is a promising source of ChrR capable of bioremediation of toxic chromium species."

Clinical • Journal

A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance. (PubMed, Arthritis Res Ther) - "MCC22 is a novel bivalent ligand that targets CCR5 and MOR. Our findings demonstrate that MCC22 provides highly potent analgesia and improved functional outcomes in a model of inflammatory arthritis, without inducing typical opioid tolerance. These findings suggest that MCC22 or similar compounds could be used to treat the pain associated with inflammatory arthritis and related conditions, while minimizing the risks typically associated with chronic opioid use."

Journal • Preclinical